| Company Name: |
DC Chemicals |
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
|
| | Benzamide, 4-(1H-imidazol-5-yl)-N-[2-(2-methyl-1H-indol-3-yl)ethyl]- Basic information |
| | Benzamide, 4-(1H-imidazol-5-yl)-N-[2-(2-methyl-1H-indol-3-yl)ethyl]- Chemical Properties |
| Boiling point | 718.8±60.0 °C(Predicted) | | density | 1.263±0.06 g/cm3(Predicted) | | pka | 12.77±0.10(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | Benzamide, 4-(1H-imidazol-5-yl)-N-[2-(2-methyl-1H-indol-3-yl)ethyl]- Usage And Synthesis |
| Uses | TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases[1]. | | References | [1] Amaradhi R, Mohammed S, Banik A, et al. Second-generation prostaglandin receptor EP2 antagonist, TG8-260, with high potency, selectivity, oral bioavailability, and anti-inflammatory properties[J]. ACS Pharmacology & Translational Science, 2022, 5(2): 118-133. |
| | Benzamide, 4-(1H-imidazol-5-yl)-N-[2-(2-methyl-1H-indol-3-yl)ethyl]- Preparation Products And Raw materials |
|